Ranked #7,237 of 8,699 institutional investors
B Group, Inc.
Dallas, TX
$143M
US stock portfolio at live prices · today −$3.0M (−2.07%)
Market closed. Prices as of Nov 20, 7:11 AM ET
- Value at quarter end (Q3 2026)
- $162M
- Change from Q2 2026
- −$14.1M (−7.98%)
- Positions
- 19 · 1 new, 0 sold out
- Filed
- Nov 16, 2026
Holdings
Q3 2026 13F, live pricesADMA 30.4%NRXP 7.63%PALI 7.39%PRAX 7.23%SGHT 7.21%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| ADMA ADMA Biologics, Inc. | 3,262,542 | $43.5M | 30.4% | Unchanged |
| NRXP NRx Pharmaceuticals, Inc. | 4,277,200 | $10.9M | 7.63% | Added +5% |
| PALI Palisade Bio, Inc. | 11,414,285 | $10.6M | 7.39% | Unchanged |
| PRAX Praxis Precision Medicines, Inc. | 33,237 | $10.3M | 7.23% | Unchanged |
| SGHT Sight Sciences, Inc. | 970,000 | $10.3M | 7.21% | Unchanged |
| ZLAB Zai Lab Limited | 450,646 | $9.9M | 6.91% | Unchanged |
| TSHA Taysha Gene Therapies, Inc. | 1,800,556 | $6.8M | 4.75% | Unchanged |
| SYRE Spyre Therapeutics, Inc. | 62,500 | $6.1M | 4.27% | Reduced −11% |
| ORKA Oruka Therapeutics, Inc. | 55,000 | $5.4M | 3.75% | Reduced −27% |
| AURA Aura Biosciences, Inc. | 764,243 | $5.3M | 3.73% | Unchanged |
| FTH Faeth Therapeutics, Inc. | 610,169 | $5.3M | 3.71% | Unchanged |
| ASMB Assembly Biosciences, Inc. | 175,706 | $4.0M | 2.77% | Unchanged |
| CLLS Cellectis S.A. | 3,281,501 | $3.2M | 2.26% | Unchanged |
| IOVA Iovance Biotherapeutics, Inc. | 425,000 | $3.1M | 2.17% | Reduced −72% |
| GPCR Structure Therapeutics Inc. | 180,000 | $3.1M | 2.16% | Added +29% |
| RARE Ultragenyx Pharmaceutical Inc. | 135,000 | $2.3M | 1.63% | Unchanged |
| DRUG Bright Minds Biosciences Inc. | 95,000 | $2.0M | 1.38% | Added +41% |
| QTTB Q32 Bio Inc. | 65,000 | $551K | 0.39% | New |
| FHTX Foghorn Therapeutics Inc. | 200,000 | $356K | 0.25% | Unchanged |